Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,100

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

January 31, 2028

Study Completion Date

July 31, 2028

Conditions
Prostate Cancer
Interventions
DRUG

Darolutamide

2 x 300mg oral tablets twice daily for 96 weeks

DRUG

Placebo oral tablet

2 oral tablets twice daily for 96 weeks

DRUG

Luteinizing Hormone-Releasing Hormone Analog

All participants are to receive standard background therapy with an LHRHA, as per standard of care. The choice of LHRHA is at the discretion of the treating clinician.

RADIATION

External Beam Radiotherapy

All participants are to receive standard background therapy with curative-intent RT to the prostate or prostate bed as well as the pelvic lymph nodes using EBRT.

Trial Locations (93)

1023

Auckland City Hospital, Auckland

2010

St Vincent's Public Hospital, Sydney

2031

Prince of Wales Hospital, Sydney

2050

Chris O'Brien Lifehouse, Sydney

2065

Northern Cancer Institute, Sydney

2076

Sydney Adventist Hospital, Sydney

2170

Liverpool Hospital, Sydney

2217

St George Hospital, Sydney

2250

Gosford Hospital, Gosford

2290

GenesisCare Newcastle, Newcastle

2298

Calvary Mater Newcastle, Newcastle

2500

Wollongong Hospital, Wollongong

2541

Shoalhaven District Memorial Hospital, Nowra

2560

Campbelltown hospital, Sydney

2640

Border Medical Oncology Research Unit, Albury

3000

Peter MacCallum Cancer Centre, Melbourne

3004

The Alfred Hospital, Melbourne

3021

Sunshine Hospital, St Albans

3128

Box Hill Hospital, Box Hill

3144

GenesisCare Cabrini (Gandel Wing), Cabrini Hospital Malvern, Malvern

3165

Peter MacCallum Cancer Centre (Moorabbin Campus), Bentleigh East

3550

Peter MacCallum Cancer Centre - Bendigo Campus, Bendigo

4029

Royal Brisbane and Women's Hospital, Herston

4101

ROPART, Brisbane

4102

Princess Alexandra Hospital, Woolloongabba

4215

Icon Cancer Centre, Southport

4442

Palmerston North Hospital, Palmerston North

4814

Townsville Hospital, Townsville

5037

Ashford Cancer Centre Research, Kurralta Park

6006

Sir Charles Gairdner Hospital, Nedlands

6143

Fiona Stanley Hospital, Murdoch

7000

Icon Cancer Centre Hobart, Hobart

Royal Hobart Hospital, Hobart

8011

Christchurch Hospital, Christchurch

10016

New York University Langone Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11501

New York University Langone Long Island, Mineola

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

45409

Dayton Physicians Network, Kettering

68130

XCancer Omaha/Urology Cancer Center, Omaha

87109

New Mexico Oncology and Hematology Specialists, Albuquerque

98109

Seattle Cancer Care Alliance, Seattle

02215

Dana-Farber Cancer Institute, Boston

02135

Dana Farber Cancer Institute - St. Elizabeth's, Brighton

01805

Lahey Hospital and Medical Center, Burlington

01757

Dana Farber Cancer Institute - Milford, Milford

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07013

New Jersey Urology Saddle Brook, Clifton

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

08043

New Jersey Urology Voorhees, Voorhees Township

Unknown

Latrobe Regional Hospital, Traralgon

Centre Hospitalier de l'Universite de Montreal, Montreal

Royal Marsden Hospital, London

T6G 1Z2

Cross Cancer Institute, Edmonton

V3V 1Z2

BC Cancer Agency (BCCA) Fraser Valley, Surrey

R7A 2B3

Western Manitoba Cancer Centre - Prairie Mountain Health, Brandon

R3E 0V9

CancerCare Manitoba, Winnipeg

E2L 4L2

Regional Health Authority B, Zone 2 Saint John Regional Hospital, Saint John

A1B 3V6

Dr. H. Bliss Murphy Cancer Centre, St. John's, St. John's

K7L 2V7

Kingston Health Sciences Centre, Kingston

B3H 1V7

Queen Elizabeth II Health Sciences Centre, London

P6B 0A8

Sault Area Hospital - Algoma District Cancer Program, Sault Ste. Marie

K1H 8L6

Ottawa Hospital Research Institute, Toronto

M4N 3M5

Odette Cancer Centre - Sunnybrook Hospital, Toronto

M5G 2M9

Princess Margaret Cancer Centre, Toronto

J4V 2H1

Centre Integre de Sante et de Services Sociaux de la Monteregie Centre, Greenfield Park

H3T 1E2

Jewish General Hospital, Montreal

G1R 2J6

Hôtel-Dieu de Québec, Québec

J1H 5N4

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke

S4T 7T1

Allan Blair Cancer Centre, Regina

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

G8Z 3R9

Centre Hospitalier Regional de Trois-Rivieres, Québec

D06 E1C9

St. Luke's Hospital, Rathgar

T12 EC8P

Cork University Hospital, Cork

T23

Bon Secours Hospital Cork in association with UPMC Hillman Centre, Cork

D07 A8NN

Mater Misericordiae University Hospital, Dublin

D07 WKW8

Mater Private Dublin, Dublin

D08 T6T8

St Luke's Radiation Oncology Network at St James's Hospital, Dublin

D18 AK68

Beacon Private Hospital Dublin, Dublin

D24 NR0A

Tallaght University Hospital, Dublin

H91 YR71

Galway University Hospital, Galway

AB25 2ZN

Aberdeen Royal Infirmary, Aberdeen

TN24 0LZ

William Harvey Hospital, Ashford

BA1 3NG

Royal United Hospital Bath, Bath

BT9 7AB

Belfast City Hospital, Belfast

CT1 3NG

Kent and Canterbury Hospital, Canterbury

EH4 2XU

Western General Hospital, Edinburgh

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

SE1 9RT

Guy's and St Thomas Hospital, London

NG5 1PB

Nottingham University Hospitals NHS Trust - Nottingham City Hospital, Nottingham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

OTHER

collaborator

Bayer

INDUSTRY

collaborator

Cancer Trials Ireland

NETWORK

collaborator

Canadian Cancer Trials Group

NETWORK

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Prostate Cancer Clinical Trials Consortium

OTHER

lead

University of Sydney

OTHER

NCT04136353 - Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate | Biotech Hunter | Biotech Hunter